Why Attend LEAP HR: Emerging Biopharma?
Running a lean HR function inside an emerging or clinical-stage biopharma company is unlike anything else in the industry.
HR leaders are making decisions that affect drug development timelines, workforce planning, culture through clinical uncertainty, talent acquisition, retention, and organizational growth, often with limited resources and no established playbook. The realities of operating in a pre-commercial environment are fundamentally different from those faced by large pharma organizations.
That's why LEAP HR: Emerging Biopharma was created.
Now in its 6th year, this is the only event dedicated exclusively to helping HR leaders in emerging biopharma benchmark their people strategies, learn from peers facing similar challenges, and build the networks needed to navigate an increasingly complex market.
Event Highlights
Egetis Therapeutics kept its US commercial launch team fully intact, using AI-driven retention intelligence to redirect three hours per person weekly back to critical work.
Parabilis closed the biggest biotech IPO in history, scaling from 165 to over 200 employees while deliberately preserving the culture that built its early success.
Savara retained 11 of 12 targeted hires, over 90%, through a 10-month hiring delay, using personalized outreach and transparent leadership to protect long-term employer brand.
TScan scaled from 25 to over 200 employees, then navigated a 30% reduction in force while sustaining industry-leading retention throughout the transition.
City Therapeutics scaled from 35 to nearly 100 employees, advancing three programs to clinic within two and a half years of coming out of stealth.
Bicara Therapeutics sustained zero employee turnover and a time-to-hire under 40 days, against an industry average of 90, while rolling out refreshed company values.
Ventus Therapeutics reduced its team from around 100 employees to 35, protecting its clinical trial budget while retaining talent with almost no attrition.
Spero Therapeutics handled its reduction in force with transparency and fairness, expecting at least 75% of its next growth phase from returning employees.
Attending Companies Include